Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling.

Feng Y, Wang X, Suryawanshi S, Bello A, Roy A.

CPT Pharmacometrics Syst Pharmacol. 2019 Jul 23. doi: 10.1002/psp4.12454. [Epub ahead of print]

2.

Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.

Bajaj G, Suryawanshi S, Roy A, Gupta M.

Br J Clin Pharmacol. 2019 May 29. doi: 10.1111/bcp.13996. [Epub ahead of print]

PMID:
31140642
3.

Microcosm study of atrazine bioremediation by indigenous microorganisms and cytotoxicity of biodegraded metabolites.

Kolekar PD, Patil SM, Suryavanshi MV, Suryawanshi SS, Khandare RV, Govindwar SP, Jadhav JP.

J Hazard Mater. 2019 Jul 15;374:66-73. doi: 10.1016/j.jhazmat.2019.01.023. Epub 2019 Jan 11.

PMID:
30978632
4.

Enhanced inulinase production by Fusarium solani JALPK from invasive weed using response surface methodology.

Kamble PP, Suryawanshi SS, Jadhav JP, Attar YC.

J Microbiol Methods. 2019 Apr;159:99-111. doi: 10.1016/j.mimet.2019.02.021. Epub 2019 Mar 2.

PMID:
30831141
5.

The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer.

Andersen CL, Boisen MM, Sikora MJ, Ma T, Tseng G, Suryawanshi S, Vlad A, Elishaev E, Edwards RP, Oesterreich S.

Horm Cancer. 2018 Dec;9(6):399-407. doi: 10.1007/s12672-018-0350-9. Epub 2018 Oct 9.

PMID:
30302736
6.

Tetrahymena RIB72A and RIB72B are microtubule inner proteins in the ciliary doublet microtubules.

Stoddard D, Zhao Y, Bayless BA, Gui L, Louka P, Dave D, Suryawanshi S, Tomasi RF, Dupuis-Williams P, Baroud CN, Gaertig J, Winey M, Nicastro D.

Mol Biol Cell. 2018 Oct 15;29(21):2566-2577. doi: 10.1091/mbc.E18-06-0405. Epub 2018 Aug 22.

7.

Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.

Passey C, Suryawanshi S, Sanghavi K, Gupta M.

AAPS J. 2018 Feb 26;20(2):35. doi: 10.1208/s12248-018-0194-9. Review.

PMID:
29484520
8.

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

Lee SH, Gantz I, Round E, Latham M, O'Neill EA, Ceesay P, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

BMC Endocr Disord. 2017 Nov 6;17(1):70. doi: 10.1186/s12902-017-0219-x.

9.

FRET Between Riboflavin and 9-Anthraldehyde Based Fluorescent Organic Nanoparticles Possessing Antibacterial Activity.

Mahajan PG, Dige NC, Suryawanshi SB, Dalavi DK, Kamble AA, Bhopate DP, Kadam AN, Kondalkar VV, Kolekar GB, Patil SR.

J Fluoresc. 2018 Jan;28(1):207-215. doi: 10.1007/s10895-017-2183-2. Epub 2017 Oct 27.

PMID:
29079896
10.

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.

Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E.

Diabetes Res Clin Pract. 2018 Apr;138:253-261. doi: 10.1016/j.diabres.2017.10.018. Epub 2017 Oct 24.

11.

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.

Gantz I, Sokolova L, Jain L, Iredale C, O'Neill EA, Wei Z, Lam R, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Clin Ther. 2017 Oct;39(10):2024-2037. doi: 10.1016/j.clinthera.2017.08.009. Epub 2017 Sep 18.

12.

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E.

Cardiovasc Diabetol. 2017 Sep 11;16(1):112. doi: 10.1186/s12933-017-0593-8.

13.

Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.

Suryawanshi SL, Shewade HD, Nagaraja SB, Nair SA, Parmar M.

Public Health Action. 2017 Jun 21;7(2):116-122. doi: 10.5588/pha.17.0013.

14.

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Curr Med Res Opin. 2017 Oct;33(10):1861-1868. doi: 10.1080/03007995.2017.1335638. Epub 2017 Jun 28.

PMID:
28548024
15.

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, Ceesay P, Suryawanshi S, Engel SS.

Curr Med Res Opin. 2017 Oct;33(10):1853-1860. doi: 10.1080/03007995.2017.1335637. Epub 2017 Jun 23.

PMID:
28547998
16.

Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.

Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, Vezina HE, McHenry MB, Waxman IM, Achanta A, Bello A, Roy A, Agrawal S.

Ann Oncol. 2017 Aug 1;28(8):2002-2008. doi: 10.1093/annonc/mdx235.

17.

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.

Wong H, Bohnert T, Damian-Iordache V, Gibson C, Hsu CP, Krishnatry AS, Liederer BM, Lin J, Lu Q, Mettetal JT, Mudra DR, Nijsen MJMA, Schroeder P, Schuck E, Suryawanshi S, Trapa P, Tsai A, Wang H, Wu F.

Drug Discov Today. 2017 Oct;22(10):1447-1459. doi: 10.1016/j.drudis.2017.04.015. Epub 2017 May 2. Review.

PMID:
28476536
18.

Carbazole based nanoprobe for selective recognition of Fe3+ ion in aqueous medium: Spectroscopic insight.

Suryawanshi SB, Mahajan PG, Bodake AJ, Kolekar GB, Patil SR.

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Aug 5;183:232-238. doi: 10.1016/j.saa.2017.04.010. Epub 2017 Apr 18.

PMID:
28454076
19.

A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E.

Int J Clin Pract. 2017 Jun;71(6). doi: 10.1111/ijcp.12955. Epub 2017 Apr 27.

20.

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.

Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2017 Nov;19(11):1587-1593. doi: 10.1111/dom.12983. Epub 2017 Jul 7.

PMID:
28432745
21.
22.

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Apr;40(4):494-501. doi: 10.2337/dc16-1135. Epub 2017 Jan 5.

PMID:
28057693
23.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

24.

Gossypiboma: An Unusual Presentation as Perforation and Intraluminal Migration.

Tiwari VK, Mahey RK, Patil R, Bakale N, Suryawanshi S.

J Clin Diagn Res. 2016 Sep;10(9):PD01-PD02. Epub 2016 Sep 1.

25.

Identification and quantification of indoor air pollutant sources within a residential academic campus.

Suryawanshi S, Chauhan AS, Verma R, Gupta T.

Sci Total Environ. 2016 Nov 1;569-570:46-52. doi: 10.1016/j.scitotenv.2016.06.061. Epub 2016 Jun 18.

PMID:
27328399
26.

Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis.

Liao G, Zhou Z, Suryawanshi S, Mondal MA, Guo Z.

ACS Cent Sci. 2016 Apr 27;2(4):210-8. doi: 10.1021/acscentsci.5b00364. Epub 2016 Apr 4.

27.

A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.

Zhou Z, Liao G, Mandal SS, Suryawanshi S, Guo Z.

Chem Sci. 2015 Dec 1;6(12):7112-7121. Epub 2015 Sep 22.

28.

Antibiotic Prescribing Pattern in a Tertiary Level Neonatal Intensive Care Unit.

Suryawanshi S, Pandit V, Suryawanshi P, Panditrao A.

J Clin Diagn Res. 2015 Nov;9(11):FC21-4. doi: 10.7860/JCDR/2015/14764.6807. Epub 2015 Nov 1.

29.

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.

Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, Kaufman KD, Engel SS.

Diabetes Care. 2015 Nov;38(11):2106-14. doi: 10.2337/dc15-0109. Epub 2015 Aug 26.

PMID:
26310692
30.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM.

Pharmacol Res Perspect. 2015 Aug;3(4):e00159. doi: 10.1002/prp2.159. Epub 2015 Jul 6.

31.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

32.

Transbilayer lipid interactions mediate nanoclustering of lipid-anchored proteins.

Raghupathy R, Anilkumar AA, Polley A, Singh PP, Yadav M, Johnson C, Suryawanshi S, Saikam V, Sawant SD, Panda A, Guo Z, Vishwakarma RA, Rao M, Mayor S.

Cell. 2015 Apr 23;161(3):581-594. doi: 10.1016/j.cell.2015.03.048.

33.

Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.

Schuck E, Bohnert T, Chakravarty A, Damian-Iordache V, Gibson C, Hsu CP, Heimbach T, Krishnatry AS, Liederer BM, Lin J, Maurer T, Mettetal JT, Mudra DR, Nijsen MJ, Raybon J, Schroeder P, Schuck V, Suryawanshi S, Su Y, Trapa P, Tsai A, Vakilynejad M, Wang S, Wong H.

AAPS J. 2015 Mar;17(2):462-73. doi: 10.1208/s12248-014-9716-2. Epub 2015 Jan 29.

34.

Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents.

Tiwari A, Kumar S, Shivahare R, Kant P, Gupta S, Suryawanshi SN.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):410-3. doi: 10.1016/j.bmcl.2014.09.078. Epub 2014 Oct 2.

PMID:
25475205
35.

Spectral analysis of the emission current noise exhibited by few layer WS2 nanosheets emitter.

Suryawanshi SR, Kolhe PS, Rout CS, Late DJ, More MA.

Ultramicroscopy. 2015 Feb;149:51-7. doi: 10.1016/j.ultramic.2014.10.004. Epub 2014 Oct 29.

PMID:
25436929
36.

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RP, Vlad AM.

Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.

37.

Vapor-liquid-solid growth of one-dimensional tin sulfide (SnS) nanostructures with promising field emission behavior.

Suryawanshi SR, Warule SS, Patil SS, Patil KR, More MA.

ACS Appl Mater Interfaces. 2014 Feb 12;6(3):2018-25. doi: 10.1021/am405039j. Epub 2014 Jan 27.

PMID:
24432697
38.

Bioavailability enhancement of ondansetron after nasal administration of Caesalpinia pulcherrima-based microspheres.

Suryawanshi SR, Thakare NP, More DP, Thombre NA.

Drug Deliv. 2015;22(7):894-902. doi: 10.3109/10717544.2013.860205. Epub 2013 Nov 26.

PMID:
24279581
39.

Quantitative Extrapolation: An Approach to Validation of Adult Drug Efficacy in Pediatric Subjects.

Leil TA, Zee P, Suryawanshi S, Male C, Portman R.

Ther Innov Regul Sci. 2013 Sep;47(5):557-565. doi: 10.1177/2168479013500286.

PMID:
30235580
40.

Design, synthesis and biological evaluation of aryl pyrimidine derivatives as potential leishmanicidal agents.

Suryawanshi SN, Kumar S, Shivahare R, Pandey S, Tiwari A, Gupta S.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5235-8. doi: 10.1016/j.bmcl.2013.06.060. Epub 2013 Jun 29.

PMID:
23910597
41.

Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.

Suryawanshi SN, Kumar S, Tiwari A, Shivahare R, Chhonker YS, Pandey S, Shakya N, Bhatta RS, Gupta S.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3979-82. doi: 10.1016/j.bmcl.2013.04.025. Epub 2013 Apr 26.

PMID:
23673014
42.

Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents.

Suryawanshi SN, Tiwari A, Kumar S, Shivahare R, Mittal M, Kant P, Gupta S.

Bioorg Med Chem Lett. 2013 May 15;23(10):2925-8. doi: 10.1016/j.bmcl.2013.03.055. Epub 2013 Mar 26.

PMID:
23582274
43.

Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X.

Clin Cancer Res. 2013 Mar 1;19(5):1213-24. doi: 10.1158/1078-0432.CCR-12-2726. Epub 2013 Jan 29.

44.

Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles.

Tiwari A, Kumar S, Suryawanshi SN, Mittal M, Vishwakarma P, Gupta S.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):248-51. doi: 10.1016/j.bmcl.2012.10.110. Epub 2012 Nov 2.

PMID:
23177254
45.

Chemotherapy of leishmaniasis. Part XI: synthesis and bioevaluation of novel isoxazole containing heteroretinoid and its amide derivatives.

Suryawanshi SN, Tiwari A, Chandra N, Ramesh, Gupta S.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6559-62. doi: 10.1016/j.bmcl.2012.09.024. Epub 2012 Sep 15.

PMID:
23031597
46.

Chemotherapy of leishmaniasis. Part IX: synthesis and bioevaluation of aryl substituted ketene dithioacetals as antileishmanial agents.

Kumar S, Tiwari A, Suryawanshi SN, Mittal M, Vishwakarma P, Gupta S.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6728-30. doi: 10.1016/j.bmcl.2012.08.096. Epub 2012 Sep 13.

PMID:
23031588
47.

Left atrial spindle cell sarcoma - case report.

Mehta N, Desai A, Shivdasani B, Suryawanshi S, Mehta AB, Behranwala A, Dhabhar B.

Indian Heart J. 2012 Jul-Aug;64(4):416-9. doi: 10.1016/j.ihj.2012.06.008. Epub 2012 Jun 22.

48.

Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.

Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T.

Curr Med Res Opin. 2012 Aug;28(8):1289-96. doi: 10.1185/03007995.2012.707119. Epub 2012 Jul 6.

PMID:
22738801
49.

Serum ferritin-a novel risk factor in acute myocardial infarction.

Holay MP, Choudhary AA, Suryawanshi SD.

Indian Heart J. 2012 Mar-Apr;64(2):173-7. doi: 10.1016/S0019-4832(12)60056-X. Epub 2012 Apr 28.

50.

Total synthesis of sialic acid by a sequential rhodium-catalyzed aziridination and Barbier allylation of D-glycal.

Lorpitthaya R, Suryawanshi SB, Wang S, Pasunooti KK, Cai S, Ma J, Liu XW.

Angew Chem Int Ed Engl. 2011 Dec 9;50(50):12054-7. doi: 10.1002/anie.201104516. Epub 2011 Oct 18. No abstract available.

PMID:
22006859

Supplemental Content

Loading ...
Support Center